Active caspase-1 processes and releases IL-1/IL-18, which recruit neutrophils -culminating in alveolar damage and edema
The standard approach begins with a 0.25 mg subcutaneous injection once weekly, then increases by 0.25 mg every four weeks, progressing through 0.5 mg, 0.75 mg, 1.0 mg, 1.5 mg, and potentially reaching 2.0 mg or 2.4 mg as maintenance doses
Specifically, this sequence sequesters G-actin monomers, reducing filamentous actin polymerization and promoting the cellular migration required for wound closure and tissue repair
LANSM insiste depuis plusieurs mois sur le risque de msusage, notamment vise esthtique, et sur la ncessit de respecter strictement les indications de lAMM
Available at: Continue reading [22] Zhang, W., Fan, M., Wang, C